8 To 10 Amino Acid Residues In Defined Sequence Patents (Class 530/328)
-
Publication number: 20140315784Abstract: The present invention relates to compounds which bind to Beta Trans-ducin repeat-containing protein (PTrCP), and modulate the activity of 13TrCP. In particular, the invention relates to compounds which demonstrate optimised binding to PTrCP. The invention also relates to pharmaceutical compositions comprising such compounds and the use of such compounds as medicaments, specifically for the treatment of disorders associated with aberrant protein degradation, such as cancer. The preferred binding inhibitors are peptides derived from the motive DSGXXS, e.g. DEGFWE, DDGFWD and Succinyl-EGFWE.Type: ApplicationFiled: June 27, 2012Publication date: October 23, 2014Inventors: Mark Bradley, Jeffrey George Andrew Walton, Sunay Vijaykumar Chankeshwara, Mazen Sleiman, George S. Baillie, Lucien Gibson
-
Publication number: 20140316107Abstract: Structural and functional analysis of peptide inhibitor binding to the cyclin D1 groove has been investigated and used to design peptides that provide the basis for structure-activity relationships, have improved binding and have potential for development as chemical biology probes, as potential diagnostics and as therapeutics in the treatment of proliferative diseases including cancer and inflammation.Type: ApplicationFiled: September 4, 2013Publication date: October 23, 2014Inventors: Campbell McInnes, Shu Liu
-
Publication number: 20140315824Abstract: The subject of the present invention are peptide preparations obtained via the enzymatic digestion of hair, wool, bristles, animal fur and individual peptides with sequences corresponding to individual components of a peptide preparation with antitumour activity, for use in the treatment of tumours or oncological prophylaxis as basal components or components of compositions of substances for treating tumours or components of substances used in oncological prophylaxis.Type: ApplicationFiled: December 6, 2011Publication date: October 23, 2014Applicant: Instytut Medycyny Doswiadczalnej i Klinicznej PanInventors: Andrzej Lipkowski, Sergiusz Markowicz
-
Publication number: 20140316106Abstract: A series of integrin blockers that present strong angiogenesis inhibiting performance, high integrin affinity and integrin-bonding capacity is provided. This series of integrin blockers can be adopted in treatment of solid tumors and rheumatoid arthritis. Specifically, said series of integrin blockers include polypeptide I, polypeptide II and polypeptide III (see SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3) that can be adopted in treatment of solid tumors and rheumatoid arthritis. This invention also relates to application of these three integrin-blocking polypeptides in preparation of anti-tumor drugs, wherein the tumors that can be treated include those primary or secondary cancers originated from head and neck region or other organs such as brain, thyroid, esophagus, pancreas, lung, liver, stomach, breast, kidney, gallbladder, colon, rectum, ovary, cervix, uterus, prostate, bladder and testicle, as well as melanoma and sarcomas.Type: ApplicationFiled: December 26, 2012Publication date: October 23, 2014Inventor: HANMEI XU
-
Publication number: 20140314758Abstract: Immunogenic peptides from tumor associated stromal cell antigens, including combinations of such peptides, are disclosed herein. In some examples the peptides are useful for methods of eliciting an immune response. In additional examples the peptides are useful for methods of treating cancer. Methods for decreasing vascularization of a tumor using a Protein Delta Homolog 1 (DLK1) protein or a nucleic acid encoding the protein are also disclosed.Type: ApplicationFiled: November 15, 2012Publication date: October 23, 2014Applicant: University of Pittsburgh- Of the Commonwealth System of Higher EducationInventors: Walter J. Storkus, Anamika Bose, Jennifer Lynn Taylor, Xi Zhao, Devin B. Lowe
-
Publication number: 20140315818Abstract: The invention relates to methods for altering biological parameters in a subject, such as reducing blood pressure in a subject, by displacing CLIP, using a CLIP inhibitor. The methods are useful for treating disorders such as preeclampsia and high blood pressure.Type: ApplicationFiled: November 30, 2012Publication date: October 23, 2014Inventors: Martha Karen Newell, Brett Mitchell, Evan Newell
-
Publication number: 20140315831Abstract: The present disclosure is directed to a novel class of peptide-like oligomers called peptide tertiary amides (PTAs) and a combinatorial library of PTAs along with synthetic routes for the preparation of large combinatorial libraries of these compounds. The peptide tertiary amides provide an exceptional source of high affinity and selective protein ligands that are useful as tools for biological research and as drug leads, among others.Type: ApplicationFiled: October 25, 2012Publication date: October 23, 2014Inventors: Thomas Kodadek, Yu Gao
-
Publication number: 20140309157Abstract: The present invention relates to a WNT-derived novel peptide and use thereof. WNT-derived peptide of the present invention possesses identical or similar activities to natural-occurring WNT protein, and has much higher stability and skin penetration potency than natural-occurring WNT protein. Therefore, the composition containing the present peptide not only shows excellent effects on improvement in hair loss (for example, promotion of hair growth or production of hair), but also has superior efficacies on treatment of a WNT signal transduction pathway-related disorder. In addition, the outstanding activity and stability of the present peptide described above may be greatly advantageous in application to pharmaceutical compositions, quasi-drugs and cosmetics.Type: ApplicationFiled: May 9, 2012Publication date: October 16, 2014Applicant: CAREGEN CO., LTD.Inventors: Yong Ji Chung, Eun Mi Kim
-
Publication number: 20140309126Abstract: The present disclosure provides a peptide including one or more amino acid sequence selected from a group consisting of SEQ ID NO 1 and SEQ ID NO 2 and binding specifically to a graphitic material, a phage including same, and a graphitic material including a graphitic surface on which the peptide or the phage is arranged.Type: ApplicationFiled: February 4, 2014Publication date: October 16, 2014Applicant: Korea Institute of Science and TechnologyInventors: Hyunjung YI, Ki Young LEE, Chaun JANG, Joonyeon CHANG
-
Publication number: 20140309162Abstract: The present invention relates to an antibacterial and fungicidal peptide in which a lysine and tryptophan dipeptide is repeated. More specifically, the antibacterial and fungicidal peptide of the present invention, in which lysine and tryptophan dipeptide is repeated four times, shows excellent antibacterial activities with respect to gram-positive bacteria, gram-negative bacteria and antibiotic-resistant strains by affecting the inner membrane of harmful microorganisms, has remarkable fungicidal activities with respect to pathogenic fungi and antibiotic-resistant fungi, and shows little cytotoxicity, and thus can be useful for a pharmaceutical composition, a cosmetic composition, agricultural chemicals, a food preservative, a cosmetic preservative, and a pharmaceutical preservative.Type: ApplicationFiled: June 27, 2014Publication date: October 16, 2014Applicant: Industry-Academic Cooperation Foundation, Chosun UniversityInventor: Yoon Kyung Park
-
Patent number: 8859492Abstract: It is an object of the present invention to provide improved pharmacological properties to molecules which bind to a target with low affinity (hereinafter referred to as a “ligand moiety”) through linkage of such molecules to a metal binding moiety, thereby generating a combination molecule commonly referred to as a “metallodrug” or “metallotherapeutic.” The metal binding domain of metallodrugs typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, resulting in modification of proteins and nucleic acids that are in close proximity due to binding of the ligand moiety to its target.Type: GrantFiled: May 12, 2012Date of Patent: October 14, 2014Assignee: MetalloPharm, LLCInventors: James A. Cowan, Ada S. Cowan, Donna T. Palmer
-
Patent number: 8859725Abstract: The invention provides novel healthy kidney biomarkers useful in the monitoring of renal function and in the prognosis and diagnosis of renal dysfunctions, especially those related to graft rejection. The invention further relates to methods for aiding in the evaluation, and design of personalized therapies in transplantation nephrology.Type: GrantFiled: July 31, 2008Date of Patent: October 14, 2014Assignees: Queen Mary and Westfield College, University of London, Hospital Clinic I Provincial de Barcelona, Institut de Investigacions Biomediques August PI I SunyerInventors: Luis F. Quintana Porras, Amanda Sole Gonzalez, Elisenda Bañón-Maneus, Josep M. Campistol, Pedro Rodriguez Cutillas
-
Publication number: 20140302074Abstract: The present disclosure relates generally to epitopes of an antibody known as PAT-LM1, and methods for using said epitopes.Type: ApplicationFiled: October 29, 2012Publication date: October 9, 2014Inventors: Arndt-Rene Kelter, Frank Hensel, Vic Ilag, Barbara Power, Christopher Garth Hosking
-
Publication number: 20140302124Abstract: Influenza virus infection and the resulting complications are a significant global public health problem and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Improving humoral immunity to influenza is the target of current conventional influenza vaccines, however, these are generally not cross-protective. On the contrary, cell-mediated immunity generated by primary influenza infection provides substantial protection against serologically distinct viruses due to recognition of cross-reactive T cell epitopes, often from internal viral proteins conserved between viral subtypes. Efforts are underway to develop a universal flu vaccine that would stimulate both the humoral and cellular immune responses leading to long-lived memory. Such a universal vaccine should target conserved influenza virus antibody and T cell epitopes that do not vary from strain to strain.Type: ApplicationFiled: October 18, 2012Publication date: October 9, 2014Applicant: Immunotape, Inc.Inventor: Ramila Philip
-
Publication number: 20140303073Abstract: The present invention relates to antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Orthomyxoviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of influenza virus infection in a mammal.Type: ApplicationFiled: April 11, 2014Publication date: October 9, 2014Applicant: Sarepta Therapeutics, Inc.Inventor: Patrick L. Iversen
-
Publication number: 20140303082Abstract: In the past decade a great deal of structural information for class A-GPCRs (G protein-coupled receptors) has emerged. However, the structural and electronic basis of ligand selectivity for closely related receptor subtypes such as the angiotensin receptors AT1aR and AT2R, which present completely diverse biological functions in response to the same ligand, is poorly understood. In order to monitor complex responses in biosystems it is useful to have ligands that present a gradient in terms of selectivity. In this study we present an efficient method to tune ligand selectivity for the two angiotensin II receptor subtypes, AT1aR and AT2R, by controlling aromatic-prolyl interactions in angiotensin II, through alternation of aromatic electronics. On the basis of this strategy, an AT2R selective and high affinity agonist analogue (Ki=3 nM) was obtained.Type: ApplicationFiled: June 20, 2014Publication date: October 9, 2014Inventor: Andreas Tzakos
-
Publication number: 20140296130Abstract: The present invention provides novel peptides that inhibit and/or reduce the opening of mammalian tight junctions, i.e. peptide tight junction antagonists. The present invention also provides methods for the treatment of excessive or undesirable permeability of a tissue by administering to a subject suffering from such a condition a composition comprising a peptide tight junction antagonist of the invention.Type: ApplicationFiled: June 16, 2014Publication date: October 2, 2014Inventor: Amir Tamiz
-
Publication number: 20140294902Abstract: The invention relates to disulfide-rich peptide molecules which inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against ?4?1 binding.Type: ApplicationFiled: March 28, 2014Publication date: October 2, 2014Applicant: Protagonist Therapeutics, Inc.Inventors: Ashok Bhandari, Dinesh V. Patel, Larry C. Mattheakis
-
Publication number: 20140296153Abstract: The present invention provides compounds, compositions and methods for treatment and/or prevention of neurodegenerative diseases, including but not limited to autoimmune diseases, such as multiple sclerosis, in which demyelination, (the loss of the myelin sheath that insulates the nerves) is an associated or causative feature. The data provided demonstrate the utility of the compounds and compositions according to this invention to promote oligodendrogenesis and myelination or remyelination.Type: ApplicationFiled: August 8, 2012Publication date: October 2, 2014Inventors: Sara Alves Xapeli, João José Oliveira Malva, Ricardo Augsto de Melo Reis
-
Publication number: 20140296511Abstract: Halo-organic heterocyclic compounds are described, in which at least two halogen atoms are bound to a nitrogen-containing heterocyclic terminal moiety of the compound, with at least one of such halogen atoms being iodine or bromine. Also described are polymethine dyes based on these heterocyclic compounds, and dendrimeric compounds and conjugates of such polymethine dyes. The polymethine dyes are characterized by enhanced properties, e.g., brightness, photostability, sensitivity and/or selective affinity that make them useful to target cancer cells, pathogenic microorganisms, and/or other biological materials, in applications such as photodynamic therapy, photodynamic antimicrobial chemotherapy (PACT), cancer treatment, selective removal or attachment of biological materials, antimicrobial coating materials, and other diagnostic, theranostic, spectrum shifting, deposition/growth, and analytic applications.Type: ApplicationFiled: May 5, 2014Publication date: October 2, 2014Applicant: NANOQUANTUM SCIENCES, INC.Inventors: Gary W. Jones, Anatoliy L. Tatarets, Leonid D. Patsenker
-
Publication number: 20140294901Abstract: The invention relates to disulfide-rich dimer molecules which inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against ?4?1 binding.Type: ApplicationFiled: March 28, 2014Publication date: October 2, 2014Applicant: Protagonist Therapeutics, Inc.Inventors: Ashok Bhandari, Dinesh V. Patel, Larry C. Mattheakis
-
Publication number: 20140295469Abstract: A bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage of a titin protein by a proteinase comprises contacting a sample with an antibody specifically binding said neo-epitope and determining the level of binding.Type: ApplicationFiled: July 6, 2012Publication date: October 2, 2014Inventors: Diana Julia Leeming, Morten Karsdal, Efstathios Vassiliadis
-
Publication number: 20140294942Abstract: In certain embodiments this invention provides novel antiviral peptide(s) that are effective against positive sense RNA viruses that have an internal ribosome entry site (IRES). The peptide(s) can be used to inhibit propagation of such viruses and thereby provide a effective modality for the treatment of infections such as hepatitis C, and the like.Type: ApplicationFiled: September 6, 2012Publication date: October 2, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Samuel Wheeler French, Ronik Khachatoorian, Piotr Pawel Ruchala
-
Patent number: 8846623Abstract: Cancer-targeting peptides having a PX1LX2 motif, in which X1 is His or an amino acid residue with a hydrophobic side chain and X2 is Pro, Phe, or Trp. Also disclosed herein are conjugates containing the cancer-targeting peptides and uses thereof in cancer treatment and diagnosis.Type: GrantFiled: October 25, 2011Date of Patent: September 30, 2014Assignee: Academia SinicaInventors: John Yu, Alice L. Yu, H. C. Wu, Sheng-Hung Wang, I-Ju Chen
-
Publication number: 20140287029Abstract: The invention provides a peptide comprising a human cytolytic T lymphocyte (CTL) epitope from the human tumor-associated antigen (TAA) New Gene Expressed in Prostate (NGEP), which can be used in vaccine prevention or therapy of prostate cancer, as well as a nucleic acid encoding the peptide, a vector comprising the nucleic acid, a cell comprising the peptide, nucleic acid, or vector, and compositions thereof.Type: ApplicationFiled: June 9, 2014Publication date: September 25, 2014Applicant: The United States of America, as represented by the Secretary, Department of Health and HumanInventors: Jeffrey Schlom, Kwong-Yok Tsang, Ira H. Pastan
-
Publication number: 20140287002Abstract: This invention provides novel guanylate cyclase C (GC-C) agonists and their therapeutic use. The agonists may be used either alone or in combination with one or more additional agents.Type: ApplicationFiled: March 13, 2014Publication date: September 25, 2014Inventor: Kunwar Shailubhai
-
Patent number: 8841253Abstract: The invention features methods for identifying compounds that inhibit cell death, and methods for identifying compounds that promote cell death, by blocking or accelerating, respectively, the translocation of the catalytic domain of toxins or transcription factors through the endosomal membrane into the cytosol of a cell. Also featured are methods for inhibiting cell death that include the administration of polypeptides that include a toxin consensus sequence recognized by one or more components of the cytosolic translocation factor complex.Type: GrantFiled: August 30, 2006Date of Patent: September 23, 2014Assignee: Boston Medical Center CorporationInventors: John R. Murphy, Ryan Ratts
-
Publication number: 20140274883Abstract: The subject invention pertains to novel biologically active extracts from marine algae and to biologically active fractions and components of these extracts. These extracts have been shown to possess antiviral properties. Pharmaceutical compositions comprising these extracts, or comprising biologically active fractions or components of these extracts, could be used in the treatment of viral diseases including influenza.Type: ApplicationFiled: March 24, 2014Publication date: September 18, 2014Applicants: UAB RESEARCH FOUNDATION, UNIVERSITY OF SOUTH FLORIDAInventors: Alberto VAN OLPHEN, Bill J. BAKER, Dennis E. KYLE, Cynthia BUCHER, Alan MASCHEK, James B. MCCLINTOCK, JR., Charles D. AMSLER
-
Publication number: 20140271701Abstract: The present invention concerns antibodies recognizing Mycobacterium avium paratuberculosis epitopes able to cross-reacting with the beta-cell antigen ZnT8 to be used as early biomarkers of type 1 diabetes, epitopes for in vitro prognostic and diagnostic methods suitable to reveal a risk to develop type 1 diabetes, therapies for the prevention of T1D by avoiding, controlling or monitoring Mycobacterium paratuberculosis infection.Type: ApplicationFiled: October 25, 2012Publication date: September 18, 2014Inventors: Leonardo Antonio Sechi, Roberto Mallone
-
Publication number: 20140274906Abstract: The invention is based in part on identifying a core region of ND2 responsible for interacting with Src to within residues 289-321 of ND2 and more particularly residues 307-321 or 310-321 of ND2. Peptides including, overlapping or from within this region can be used to inhibit ND2 interaction with Src Inhibition of this interaction is useful for treatment or prophylaxis of neurological diseases and disorders, pain and cancer.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: NoNO Inc.Inventors: Michael Tymianski, Rongwen Li, Jonathan David Garman
-
Publication number: 20140271483Abstract: Polymeric conjugates comprising a polymeric backbone having attached thereto a bone targeting moiety and a therapeutically active agent, wherein the bone targeting moiety is attached to one end of the polymeric backbone via a branching unit such that a molar ratio of the bone targeting moiety to the polymer is at least 2:1, are disclosed. Pharmaceutical compositions containing these conjugates and uses thereof in the treatment of bone related disorders are also disclosed.Type: ApplicationFiled: May 10, 2012Publication date: September 18, 2014Applicants: Ramont at Tel-Aviv University Ltd., Universita degli Studi di PadovaInventors: Ronit Satchi-Fainaro, Gianfranco Pasut
-
Publication number: 20140274904Abstract: The present disclosure provides peptides and constructs that inhibit mitochondrial fission, and compositions comprising the peptides or constructs. The present disclosure provides methods of reducing abnormal mitochondrial fission in a cell. Also provided are methods for designing and validating mitochondrial fission inhibitor constructs and peptides, including but not limited to, evaluating the effects of the constructs and peptides on Drp1 GTPase activity, binding of Drp1 to Fis1, reduction of mitochondrial damage, reduction in cell death, inhibition of mitochondrial fragmentation in a cell under pathological conditions, and reduced loss of neurites in primary dopaminergic neurons in a Parkinsonism cell culture.Type: ApplicationFiled: May 6, 2014Publication date: September 18, 2014Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Daria Mochly-Rosen, Xin Qi, Nir Qvit
-
Publication number: 20140271723Abstract: The present invention relates to adjuvant compositions, vaccine compositions, and methods of enhancing an immune response to an antigen.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Inventors: Shuan Shian Huang, Jung San Huang
-
Publication number: 20140271692Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumour cells which can be used in vaccine compositions for eliciting anti-tumour immune responses.Type: ApplicationFiled: December 23, 2013Publication date: September 18, 2014Applicant: IMMATICS BIOTECHNOLOGIES GMBHInventors: Harpreet SINGH, Steffen WALTER, Toni WEINSCHENK, Norbert HILF, Oliver SCHOOR, Claudia TRAUTWEIN
-
Publication number: 20140274905Abstract: The present invention generally relates to methods of modulating Cav1.2 channels and Cav1.2 channel activators.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: Duke UniversityInventors: Geoffrey S. Pitt, Adam S. Barnett, Xinhe Yin
-
Patent number: 8835375Abstract: The invention relates to analogs of angiotensins, in particular to cyclised analogs having Ang(1-8) agonistic or antagonistic activity and to cyclised Ang(1-7) analogs with agonistic or antagonistic activity and displaying improved proteolytic resistance compared to their linear counterparts. Provided is a cyclic angiotensin peptide analog comprising a thioether-bridge linkage between the amino acids corresponding to positions Tyr4 and Pro7 in naturally occurring Angiotensin. Also provided is the use of analogs in therapy, for example hypertension.Type: GrantFiled: August 7, 2007Date of Patent: September 16, 2014Assignee: Applied Nanosystems B.V.Inventors: Marijke Haas, Leonardus Dorothea Kluskens, Anneke Kuipers, Rick Rink, Sieger Adriaan Nelemans, Gert Nikolaas Moll
-
Patent number: 8834840Abstract: Compositions and/or mixtures comprising peptide amphiphile compounds comprising one or more contrast agents, as can be used in a range of magnetic resonance imaging applications.Type: GrantFiled: October 4, 2007Date of Patent: September 16, 2014Assignee: Northwestern UniversityInventors: Steve R. Bull, Thomas J. Meade, Samuel I. Stupp
-
Publication number: 20140256648Abstract: Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in cancer immunotherapy are described herein. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, provided they retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding the peptides as well as pharmaceutical agents, substances and/or compositions that include any of the peptides or nucleic acids.Type: ApplicationFiled: March 11, 2014Publication date: September 11, 2014Applicant: ONCOTHERAPY SCIENCE, INC.Inventors: Yusuke NAKAMURA, Takuya TSUNODA, Ryuji OHSAWA, Sachiko YOSHIMURA, Tomohisa WATANABE
-
Publication number: 20140255437Abstract: The present invention provides isolated epitope peptides derived from TOPK and immunogenic fragments thereof have an ability to induce cytotoxic T lymphocytes (CTLs) and thus are suitable for use in cancer immunotherapy, more particularly as cancer vaccines. The peptides of the present invention encompass both of peptides including a TOPK-derived amino acid sequence and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted and/or added, provided such modified versions have CTL inducibility. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, and pharmaceutical compositions of this invention find particular utility in either or both of the treatment and prevention of a number of cancers.Type: ApplicationFiled: October 25, 2012Publication date: September 11, 2014Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe, Gaku Nakayama
-
Publication number: 20140256639Abstract: The disclosure provides for one or more peptoids, methods of manufacture thereof, and methods of use thereof, including the use of one more peptoids in neutralizing the anticoagulant activity of heparin.Type: ApplicationFiled: February 14, 2014Publication date: September 11, 2014Inventors: Dallas L. Rabenstein, Mark H. Hamza, Bruce K. Ford
-
Publication number: 20140256638Abstract: The disclosure provides for one or more peptoids, methods of manufacture thereof, and methods of use thereof, including the use of one more peptoids in neutralizing the anticoagulant activity of heparin.Type: ApplicationFiled: February 14, 2014Publication date: September 11, 2014Inventors: Dallas L. Rabenstein, Mark H. Hamza, Bruce K. Ford
-
Patent number: 8828929Abstract: The present invention aims to provide a novel CTL epitope peptide of the SARS coronavirus. The present invention provides a peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 11, 12, 13, 15, 17, 18, 23 and 24.Type: GrantFiled: November 27, 2009Date of Patent: September 9, 2014Assignees: Nof Corporation, Saitama Medical University, Japan as Represented by Director-General of National Institute of Infectious DiseasesInventors: Masanori Matsui, Tetsuya Uchida, Hiroshi Oda
-
Patent number: 8828942Abstract: The present invention relates to peptides or polypeptides for producing medicaments for preventing and/or treating synucleinopathies.Type: GrantFiled: August 20, 2010Date of Patent: September 9, 2014Assignee: Affiris AGInventors: Markus Mandler, Harald Weninger, Radmila Santic, Christian Lahsnig
-
Patent number: 8828413Abstract: Novel peptoid oligomers are disclosed that have a formula represented by the following formula I: The peptoids demonstrate antimicrobial activity and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals including humans where microbial invasion is involved. The present cyclic and linear peptoids are particularly valuable as their effect is rapid, broad in spectrum and mostly indifferent to resistance provoked by standard antibiotics.Type: GrantFiled: February 24, 2010Date of Patent: September 9, 2014Assignee: New York UniversityInventors: Kent Kirshenbaum, Sung Bin Shin
-
Patent number: 8828928Abstract: The inventions provided herein relate to amphiphilic peptides and particles comprising the amphiphilic peptides. Such amphiphilic peptides and particles described herein can be used as a delivery system, e.g., for therapeutic or diagnostic purposes, or as cell penetration vehicles or cell transfection agents.Type: GrantFiled: August 23, 2012Date of Patent: September 9, 2014Assignee: President and Fellows of Harvard CollegeInventors: Christian Dittrich, Gaudenz Danuser
-
Publication number: 20140248300Abstract: The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 143, 147, 148, 149, 150, 152, 153, 154, 156, 160, 161, 162, 163, 166, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and/or URLC10, e.g. cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines.Type: ApplicationFiled: May 9, 2014Publication date: September 4, 2014Applicant: OncoTherapy Science, Inc.Inventors: Takuya Tsunoda, Ryuji Ohsawa
-
Publication number: 20140248603Abstract: The invention provides methods and mass-labeled peptides for use in said methods for quantifying the presence of a one or more viral proteins in a sample of a preparation containing agents which bind to said viral protein, using mass-spectroscopic analyses of the sample and standards containing known amounts of labeled and unlabeled signature peptides, in particular wherein said viral proteins are antigens in a vaccine for porcine circovirus.Type: ApplicationFiled: February 28, 2014Publication date: September 4, 2014Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.Inventors: Marc Allan EICHMEYER, Michael B. ROOF, Merrill Lynn SCHAEFFER, Eric Martin VAUGHN, Kun YANG, Jeremy Richard RUSH, Daniel John MURFIN
-
Publication number: 20140249468Abstract: Disclosed are imaging agents having the following Formula I: (I); wherein F is a near infrared fluorophore, S is an enzymatically cleavable oligopeptide, Q is a fluorescence quencher molecule, and M is a moiety selected from the group consisting of PEG or derivative thereof and a targeting ligand, and wherein F, Q and M are linked to separate amino acids of the enzymatically cleavable oligopeptide. Compositions comprising such compounds, as well as methods of use, methods of identifying a cell or a population of cells in vivo expressing a protease of interest, and methods of treating a disease through imaging are also disclosed.Type: ApplicationFiled: September 7, 2012Publication date: September 4, 2014Applicant: The United States of America,as represented by the Secretary, Department of Health and Human ServiceInventors: Xiaoyuan Chen, Seulki Lee, Lei Zhu
-
Patent number: 8822638Abstract: A peptide or peptide derivative comprising: (i)?WDLYFEIVW; (SEQ?ID?NO:?1) or (ii) a variant amino acid sequence comprising one, two, three or four L-amino acid substitutions in WDLYFEIVW (SEQ ID NO: 1); or (iii) the retro-inverso variant of the peptide or peptide derivative of either one of parts (i) and (ii), wherein said peptide or peptide derivative has procoagulant activity. A peptide or peptide derivative comprising: (i) an amino acid sequence comprising imfwydcye; or (ii) a variant amino acid sequence comprising one, two, three, four, five or six amino acid substitutions in imfwydcye, wherein said peptide or peptide derivative has procoagulant activity.Type: GrantFiled: September 21, 2011Date of Patent: September 2, 2014Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Friedrich Scheiflinger, Michael Dockal
-
Publication number: 20140243265Abstract: High-specificity antibodies can distinguish between modified (e.g, hIGF-1/Ea 3mut) and endogenous wild-type human IGF-1 proteins. These antibodies have little or no cross-reactivity with hIGF-1 or hIGF-2. They also have little or no cross-reactivity with rodent IGF-1 or IGF-2. The antibodies can be used in pharmacokinetic (PK)/pharamcodynamic (PD) assessments of IGF-1/E peptides that have been administered to humans or animals. A sandwich ELISA assay, using the antibody of the invention as a capture antibody, can quantify the mutant IGF-1/E proteins in samples.Type: ApplicationFiled: May 7, 2014Publication date: August 28, 2014Applicant: NOVARTIS AGInventors: Mara FORNARO, John XU, Yuan GAO, Rainer HILLENBRAND, Francois LEGAY, Daniela STOELLNER